Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Value of Podoplanin Expression in Oral Squamous Cell Carcinoma―A Regression Model Auxiliary to UICC Classification

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Podoplanin, a type I transmembrane glycoprotein with an effect of platelet aggregation, has been reported to be one of the possible prognostic factors of oral squamous cell carcinoma (OSCC). However, the biological significance of podoplanin is largely unclear. The aim of this study was to develop a practical model for the prediction of prognosis using the grade of podoplanin expression, and also to evaluate the biological function of podoplanin. Eighty-two specimens of patients with previously untreated OSCC, who underwent either biopsy or surgery, were histopathologically and immunohistochemically analyzed. These 82 cases were composed of 66 well-differentiated, 10 moderately differentiated and 6 poorly differentiated OSCC. Podoplanin was successfully immunostained in 78 specimens, and was detected in most cases, but the frequency of positive cells varied. The prognosis of patients with more than 50 % podoplanin-positive tumor cells was significantly poorer than that of the other patients. Multivariate hazards regression analysis suggested that a linear combination of covariates, OSCC patients with more or less than 50 % podoplanin expression, age of more or less than 70 years old, mode of invasion and T3, T4 or T2 versus T1 of the UICC T-stage classification was the most effective model for evaluating the prognosis of OSCC patients. Additionally, podoplanin expression had a significant relationship to UICC clinical stage and the expression of Ki-67. An effective regression model using podoplanin expression was developed for evaluating the prognosis of OSCC and the biological significance of podoplanin was suggested to be associated with the growth and/or progression of OSCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

OSCC:

Oral squamous cell carcinoma

VEGF:

Vascular endothelial growth factor

AIC:

Akaike’s information criterion

RR:

Relative risk

References

  1. Toyoshima M, Nakajima M, Yamori T, Tsuruo T (1995) Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. Cancer Res 55(4):767–773

    CAS  PubMed  Google Scholar 

  2. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T (2003) Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278(51):51599–51605. doi:10.1074/jbc.M309935200

    Article  CAS  PubMed  Google Scholar 

  3. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154(2):385–394. doi:10.1016/s0002-9440(10)65285-6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M (2003) T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 22(14):3546–3556. doi:10.1093/emboj/cdg342

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M (2005) Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 113(6):899–910. doi:10.1002/ijc.20656

    Article  CAS  PubMed  Google Scholar 

  6. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L (2006) Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107(3):563–569. doi:10.1002/cncr.22061

    Article  CAS  PubMed  Google Scholar 

  7. Kreppel M, Drebber U, Wedemeyer I, Eich HT, Backhaus T, Zoller JE, Scheer M (2011) Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Oncol 47(9):873–878. doi:10.1016/j.oraloncology.2011.06.508

    Article  CAS  PubMed  Google Scholar 

  8. Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE (2010) Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch 456(5):473–482. doi:10.1007/s00428-010-0915-7

    Article  CAS  PubMed  Google Scholar 

  9. Bartuli FN, Luciani F, Caddeo F, Compagni S, Piva P, Ottria L, Arcuri C (2012) Podoplanin in the development and progression of oral cavity cancer: a preliminary study. Oral Implantol (Rome) 5(2–3):33–41

    CAS  Google Scholar 

  10. Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, Kundu S, Shingaki S, Saito C, Saku T (2011) Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology 78(3):171–180. doi:10.1159/000324926

    Article  CAS  PubMed  Google Scholar 

  11. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M (2005) Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 26(4):195–200. doi:10.1159/000086952

    Article  CAS  PubMed  Google Scholar 

  12. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T (2004) Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23(52):8552–8556. doi:10.1038/sj.onc.1207869

    Article  CAS  PubMed  Google Scholar 

  13. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M (2006) Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 448(4):493–499. doi:10.1007/s00428-005-0133-x

    Article  CAS  PubMed  Google Scholar 

  14. Wu HM, Ren GX, Wang LZ, Zhang CY, Chen WT, Guo W (2012) Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Report 6(2):271–274. doi:10.3892/mmr.2012.911

    CAS  Google Scholar 

  15. Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N (2011) High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis. Oncol Rep 25(3):599–607. doi:10.3892/or.2011.1141

    CAS  PubMed  Google Scholar 

  16. Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, Umezu H, Sugai M, Endo N (2010) Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol Int 60(3):193–202. doi:10.1111/j.1440-1827.2009.02510.x

    Article  CAS  PubMed  Google Scholar 

  17. Zustin J, Scheuer HA, Friedrich RE (2010) Podoplanin expression in human tooth germ tissues and cystic odontogenic lesions: an immunohistochemical study. J Oral Pathol Med 39(1):115–120. doi:10.1111/j.1600-0714.2009.00853.x

    Article  CAS  PubMed  Google Scholar 

  18. Gonzalez-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, Yoshida N, Kikuchi K, Ide F, Sakashita H, Kusama K (2010) Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med 39(1):103–109. doi:10.1111/j.1600-0714.2009.00818.x

    Article  CAS  PubMed  Google Scholar 

  19. Padgett DM, Cathro HP, Wick MR, Mills SE (2008) Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol 32(1):123–127. doi:10.1097/PAS.0b013e31814faacf

    Article  PubMed  Google Scholar 

  20. Tateyama H, Sugiura H, Yamatani C, Yano M (2011) Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome. Hum Pathol 42(4):533–540. doi:10.1016/j.humpath.2010.08.012

    Article  CAS  PubMed  Google Scholar 

  21. Tong L, Yuan S, Feng F, Zhang H (2012) Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus 25(1):72–80. doi:10.1111/j.1442-2050.2011.01211.x

    Article  CAS  PubMed  Google Scholar 

  22. Rodrigo JP, Garcia-Carracedo D, Gonzalez MV, Mancebo G, Fresno MF, Garcia-Pedrero J (2010) Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol Cancer 9:48. doi:10.1186/1476-4598-9-48

    Article  PubMed Central  PubMed  Google Scholar 

  23. Suzuki H, Onimaru M, Koga T, Takeshita M, Yano T, Maehara Y, Nakamura S, Sueishi K (2011) High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathol Res Pract 207(2):111–115. doi:10.1016/j.prp.2010.11.006

    Article  CAS  PubMed  Google Scholar 

  24. Seki S, Fujiwara M, Matsuura M, Fujita S, Ikeda H, Asahina I, Ikeda T (2011) Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol 47(7):588–593. doi:10.1016/j.oraloncology.2011.04.013

    Article  CAS  PubMed  Google Scholar 

  25. Jakobsson PA, Eneroth CM, Killander D, Moberger G, Martensson B (1973) Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol 12(1):1–8

    Article  CAS  PubMed  Google Scholar 

  26. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166(3):913–921. doi:10.1016/s0002-9440(10)62311-5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Akaike H (1973) Information theory and an extention of the maximum likelihood principle. 2nd International Symposium on Information Theory. Budapest. First published

  28. Ihaka R, Gentleman R (1996) R: a language for data analysis and graphics. J Comp Graph Stat 5:299–314

    Google Scholar 

  29. Astarita JL, Acton SE, Turley SJ (2012) Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 3:283. doi:10.3389/fimmu.2012.00283

    PubMed Central  PubMed  Google Scholar 

  30. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi A, Gruber S, Kunstfeld R, Moch H, Detmar M (2010) Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 177(2):1004–1016. doi:10.2353/ajpath.2010.090703

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Klimowicz AC, Bose P, Nakoneshny SC, Dean M, Huang L, Chandarana S, Magliocco AM, Wayne Matthews T, Brockton NT, Dort JC (2012) Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. Eur J Cancer 48(14):2166–2174. doi:10.1016/j.ejca.2012.04.010

    Article  CAS  PubMed  Google Scholar 

  32. Mashhadiabbas F, Mahjour F, Mahjour SB, Fereidooni F, Hosseini FS (2012) The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 114(2):240–250. doi:10.1016/j.oooo.2012.04.009

    Article  PubMed  Google Scholar 

  33. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26(3):354–360. doi:10.1200/jco.2007.13.4072

    Article  PubMed  Google Scholar 

  34. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A (2008) Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 373(1):36–41. doi:10.1016/j.bbrc.2008.05.163

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports and Technology of Japan (Grant no. 25462865) and the Nagasaki University research fund for the Department of Oral Pathology.

Author information

Authors and Affiliations

  1. Department of Oral Pathology and Bone Metabolism, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Sachiko Seki, Shuichi Fujita & Tohru Ikeda

  2. Department of Clinical Pathology, Japanese Red Cross Medical Center, Tokyo, Japan

    Mutsunori Fujiwara

  3. Bioinformatics Group, Genome Center of JFCR, and Division of Cancer Genomics, Cancer Institute of JFCR, Japanese Foundation for Cancer Research, Tokyo, Japan

    Masaaki Matsuura

  4. Department of Regenerative Oral Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Hisazumi Ikeda & Izumi Asahina

  5. Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    Masahiro Umeda

Authors
  1. Sachiko Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mutsunori Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaaki Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shuichi Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hisazumi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahiro Umeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Izumi Asahina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tohru Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tohru Ikeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seki, S., Fujiwara, M., Matsuura, M. et al. Prognostic Value of Podoplanin Expression in Oral Squamous Cell Carcinoma―A Regression Model Auxiliary to UICC Classification. Pathol. Oncol. Res. 20, 521–528 (2014). https://doi.org/10.1007/s12253-013-9723-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9723-0

Keywords

Search

Navigation